Literature DB >> 3501042

Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors.

E Lotzová1, C A Savary, R B Herberman.   

Abstract

We have demonstrated that unstimulated highly-enriched NK cells have the capability to inhibit the growth of fresh clonogenic leukemic cells from AML, CML and preleukemic patients. The NK-cell population mediating antileukemic reactivity exhibited LGL morphology and NKH1 and CD16 phenotype. The inhibition of leukemic growth could be mediated by cell-to-cell contact or by soluble factor produced by NK cells. Antileukemia activity was only detectable when enriched population of LGL was utilized; NW-filtered lymphocyte population did not exhibit leukemia-inhibitory effect. However, such activity could be generated after culture of the latter effector cells with IL-2. The leukemia directed IL-2 activated effector cells were characterized as NK cells. The data reported here provide new insight into host factors which may control leukemia growth and indicate the possible future application of NK cells for therapy of leukemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501042     DOI: 10.1016/0145-2126(87)90158-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

Review 1.  Engineering Natural Killer Cells for Cancer Immunotherapy.

Authors:  Katayoun Rezvani; Rayne Rouce; Enli Liu; Elizabeth Shpall
Journal:  Mol Ther       Date:  2017-06-28       Impact factor: 11.454

2.  Cytotoxicity and clinical application of activated NK cells.

Authors:  E Lotzová
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease.

Authors:  B Glass; L Uharek; W Gassmann; B Focks; H Bolouri; H Loeffler; W Mueller-Ruchholtz
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

4.  Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.

Authors:  Kate Stringaris; Takuya Sekine; Ahmad Khoder; Abdullah Alsuliman; Bonnie Razzaghi; Ruhena Sargeant; Jiri Pavlu; Gill Brisley; Hugues de Lavallade; Anushruthi Sarvaria; David Marin; Stephan Mielke; Jane F Apperley; Elizabeth J Shpall; A John Barrett; Katayoun Rezvani
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

5.  Induction of cytotoxic lymphocyte subsets against leukemia by stimulation with AML blasts.

Authors:  E Lotzová; C A Savary
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

6.  Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Authors:  Maria R Baer; Stephen L George; Michael A Caligiuri; Ben L Sanford; Sandra M Bothun; Krzysztof Mrózek; Jonathan E Kolitz; Bayard L Powell; Joseph O Moore; Richard M Stone; John Anastasi; Clara D Bloomfield; Richard A Larson
Journal:  J Clin Oncol       Date:  2008-06-30       Impact factor: 44.544

7.  MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations.

Authors:  Francois Vergez; Emmanuel Treiner; Thibault Comont; Marie-Laure Nicolau-Travers; Sarah Bertoli; Christian Recher
Journal:  Cancer Immunol Immunother       Date:  2021-09-03       Impact factor: 6.968

8.  The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.

Authors:  R H Rouce; H Shaim; T Sekine; G Weber; B Ballard; S Ku; C Barese; V Murali; M-F Wu; H Liu; E J Shpall; C M Bollard; K R Rabin; K Rezvani
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

Review 9.  The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.

Authors:  Katayoun Rezvani; Rayne H Rouce
Journal:  Front Immunol       Date:  2015-11-17       Impact factor: 7.561

Review 10.  NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies.

Authors:  Kanako Shimizu; Tomonori Iyoda; Satoru Yamasaki; Norimitsu Kadowaki; Arinobu Tojo; And Shin-Ichiro Fujii
Journal:  Cancers (Basel)       Date:  2020-03-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.